Cargando…
XDR-Pseudomonas aeruginosa Outside the ICU: Is There Still Place for Colistin?
Background: Pseudomonas aeruginosa represents, among the nosocomial pathogens, one of the most serious threats, both for the severity of its clinical manifestations and its ability to develop complex profiles of resistance; Methods: we retrospectively collected the data of 21 patients admitted to a...
Autores principales: | Del Giacomo, Paola, Raffaelli, Francesca, Losito, Angela Raffaella, Fiori, Barbara, Tumbarello, Mario |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8868142/ https://www.ncbi.nlm.nih.gov/pubmed/35203796 http://dx.doi.org/10.3390/antibiotics11020193 |
Ejemplares similares
-
New Drugs for the Treatment of Pseudomonas aeruginosa Infections with Limited Treatment Options: A Narrative Review
por: Losito, Angela Raffaella, et al.
Publicado: (2022) -
Factors Associated with Inadequate Intravenous Colistin Dosages: Post Hoc Analysis of a Multicenter, Cross-Sectional Study
por: Giacobbe, Daniele Roberto, et al.
Publicado: (2021) -
Age of Antibiotic Resistance in MDR/XDR Clinical Pathogen of Pseudomonas aeruginosa
por: Kothari, Ashish, et al.
Publicado: (2023) -
Carbapenem-Resistant but Cephalosporin-Susceptible Pseudomonas aeruginosa in Urinary Tract Infections: Opportunity for Colistin Sparing
por: Gajdács, Márió
Publicado: (2020) -
223. Clinical Characteristics and Outcomes of Acinetobacter baumannii XDR and Pseudomonas aeruginosa XDR in a Tertiary Referral Medical Center in Mexico
por: Ojeda Yuren, Alicia Sarahi, et al.
Publicado: (2023)